Alchemab Therapeutics

About Alchemab Therapeutics

Alchemab Therapeutics is focused on harnessing the power of the immune system to cure diseases by leveraging adaptive immunity. They pioneer the next generation of antibody therapeutics for hard-to-treat diseases by identifying resilient individuals, such as long-term cancer survivors, and creating therapeutics from their antibodies using leading-edge science and deep learning.

Products & Services

ATLX-1282:An antibody therapeutic in Phase 1 clinical trial, also part of a significant licensing agreement.

Antibody Therapeutics Pipeline:A range of therapeutics developed for hard-to-treat diseases, as detailed in their pipeline.

Specialties

Antibody Therapeutics Adaptive Immunity Deep Learning in Drug Development Therapeutics for Hard-to-Treat Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 595000 MR: - FA: US$595,000 FAN: 595000	D: 2024-06-06 FD: 2024-06-06	1 investors

Grant Latest

2024-06-06

$595K

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jane Osbourn

Chief Executive Officer

O

Olivia Cavlan

Chief Corporate Development and Strategy Officer

R

Ralph Minter

Chief Scientific Officer

A

Alexander Hewitson

Chief Operating Officer

P

Paul Varley

Chief Development Officer

M

Malcolm Gates

Vice President of Finance

View 17 more team members with Pro

Unlock Full Team Directory

Recent News